Pharvaris的RAPIDe-3 III期Deucrictibant用于按需治疗遗传性血管性水肿发作的主要终点达到症状缓解的中位时间，在1.28小时内实现，明显快于安慰剂

2025-12-03 19:56

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001)
All secondary efficacy endpoints met (p<0.0001), including End of Progression™1 (median 17.47 minutes) and complete symptom resolution (median 11.95 hours)
Well-tolerated safety profile of deucrictibant confirmed
Efficacy and safety outcomes consistent across all HAE subtypes represented (HAE type 1, HAE type 2, and HAE with normal C1 inhibitor) and varying attack severities and locations